| 1.83 -0.07 (-3.68%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.32 |
1-year : | 4.42 |
| Resists | First : | 2.85 |
Second : | 3.78 |
| Pivot price | 2.13 |
|||
| Supports | First : | 1.33 | Second : | 1.1 |
| MAs | MA(5) : | 1.88 |
MA(20) : | 2.21 |
| MA(100) : | 3.64 |
MA(250) : | 10.8 |
|
| MACD | MACD : | -0.4  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 20.3 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 27.93 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATNF ] has closed above bottom band by 17.6%. Bollinger Bands are 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.07 - 2.08 | 2.08 - 2.09 |
| Low: | 1.69 - 1.7 | 1.7 - 1.71 |
| Close: | 1.81 - 1.83 | 1.83 - 1.85 |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Thu, 28 Mar 2024
180 Life Sciences Corp (ATNF) Up 9.45% in Premarket Trading - InvestorsObserver
Wed, 27 Mar 2024
Should You Sell 180 Life Sciences Corp (ATNF) Stock Wednesday Morning? - InvestorsObserver
Tue, 26 Mar 2024
Is 180 Life Sciences Corp (ATNF) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Thu, 14 Mar 2024
180 Life Sciences regains Nasdaq compliance with bid price - Investing.com
Mon, 11 Mar 2024
180 Life Sciences Corp board member Sir Marc Feldmann resigns - Investing.com
Thu, 07 Mar 2024
180 Life Sciences Board Reshuffle and Strategic Refocus - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 42 (K) |
| Shares Short P.Month | 15 (K) |
| EPS | -52.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -67.7 % |
| Return on Equity (ttm) | -355.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -15.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -7.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|